Biosimilars
Pertuzumab (Perjeta)
Mechanism of Action: Antibody-dependent cell cytotoxicity; Dimerisation inhibitors Drug class: Monoclonal antibodies Originator: Genentech; Roche Developer: Chugai Pharmaceutical; Dana-Farber Cancer Institute; FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCC DI CANDIOLO; Genentech; Japan Breast Cancer Research Group; Medica Scientia Innovation Research; Roche; West German Study Group Indication: Breast cancer
Market revenue of Pertuzumab
Over the past five years, Roche’s HER2-targeted therapy Perjeta (pertuzumab) has demonstrated a generally positive revenue trend, underscoring its ongoing role in breast cancer treatment. According to available industry data, Perjeta’s global sales have risen steadily through the early 2020s, with total revenue reaching around $4.5 billion in 2024—part of a longer growth trajectory since the mid-2010s. Industry sources indicate Perjeta generated roughly $4.0 billion in recent years, reflecting broader adoption in adjuvant and metastatic HER2-positive breast cancer settings and its inclusion in key combination regimens.
Market revenue of Pertuzumab (2020- 2024)
Fig 5: Market revenue of Pertuzumab
This sustained performance over the last half-decade has been supported by expanding clinical use, increasing international uptake—particularly in markets like China and Brazil—and treatment guideline endorsements that favour Perjeta’s efficacy in reducing recurrence and improving patient outcomes. Even with shifts in treatment patterns and the rise of subcutaneous alternatives like Phesgo, Perjeta has remained a core revenue contributor in Roche’s oncology portfolio. As of 2025, a consolidated full-year revenue figure for Perjeta has not yet been officially disclosed in Roche’s annual results.
The Growing Impact of Pertuzumab Biosimilars in 2026 and Beyond
The pertuzumab biosimilar landscape is rapidly evolving, with several key approvals and launches expanding global access to HER2-positive breast cancer treatment. Recent milestones include Poherdy (pertuzumab-dpzb) from Henlius/Organon, which became the first interchangeable pertuzumab biosimilar approved by the U.S. FDA in November 2025, as well as Pertuza (Alkem) and Perzea (Hetero), both launched in India around September 2025. These developments mark important steps toward broader affordability and availability of pertuzumab therapy.